Illinois is currently home to 2641 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297
Recruiting
The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. * Cohort A: Participants with relapsed or refractory MCL r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Cancer Care Specialists of Illinois ( Site 0031), Decatur, Illinois
Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Register for Updates
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858
Recruiting
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized myasthenia gravis (gMG). Myasthenia gravis is a disease that causes weakness and fatigue in muscles in the body because the nerves and muscles are not communicating properly. The aim of the study is to see how effective pozelimab and cemdisiran are when used in combination and when pozelimab and cemdisiran are used alone for patients with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Northwestern University - Parkinson's Disease and Movement Disorders Center, Chicago, Illinois
Conditions: Generalized Myasthenia Gravis
Register for Updates
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
NCT05051618
Recruiting
The purpose of this research is to examine the effects of two different exercise training regimens for managing depression and improving other health indicators among persons with multiple sclerosis (MS). The project will enroll persons with MS and major depressive disorder (MDD) between 18 and 64 years of age. The investigators will enroll a total of 146 participants. This is a Phase-II trial that compares the efficacy of an exercise training program (POWER-MS) compared with a stretching progr... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/06/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Multiple Sclerosis, Major Depressive Disorder
Register for Updates
Transforaminal Lumbar Interbody Fusion (TLIF)
NCT04073563
Recruiting
This is a global, multi-center, prospective, randomized, blinded, controlled pivotal study. Clinical and radiological evaluation will be performed preoperatively and postoperatively up to 24 months; and endpoint success will be determined at 24 months postoperatively. Overall a maximum of 600 subjects will be enrolled and treated. The purpose of the study is to provide safety and effectiveness data of Infuse™ in Transforaminal Lumbar Interbody Fusion (TLIF) procedures and to obtain indication e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Northwestern Medicine, Chicago, Illinois
Conditions: Degenerative Disease of the Lumbosacral Spine
Register for Updates
Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)
NCT04069312
Recruiting
A multi-center, randomized, 72-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/06/2025
Locations: Northwestern, Chicago, Illinois
Conditions: Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
Register for Updates
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839
Recruiting
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Northwestern University Medical Hospital, Chicago, Illinois
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Register for Updates
Stable Isotopes- Adults With Obesity
NCT07020741
Recruiting
In a crossover design, 8 participants will receive caloric drinks containing stable isotopes. In one arm of the study, participants will consume 6 hourly drinks containing two stable isotopes. Repeated blood, breath, urine, and muscle biopsies will be taken. In the second arm, participants will consume 1 drink containing 75g glucose, labeled with two stable isotopes of glucose. Periodic blood and breath will be taken over three hours.
Gender:
ALL
Ages:
Between 19 years and 59 years
Trial Updated:
06/05/2025
Locations: Freer Hall - University of Illinois, Urbana, Illinois
Conditions: Obese Patients (BMI ≥ 30 kg/m²), Glucose Metabolism, Protein Metabolism
Register for Updates
INTEGRATED CHILDHOOD ACTIVITY AND NUTRITION (ICAN) STUDY
NCT07011602
Recruiting
This study is a multi-functional integrated research and education project to prevent losses in academic achievement, cognitive function, and behavioral health among at-risk youth. The study tests the effects of a 8-week nutrition and physical activity-based program (Integrated Childhood Activity and Nutrition \[ICAN\]) to prevent summer learning loss. Outcomes include standardized academic achievement as well as executive function among 6-10-year-olds affected by poverty. The nutrition componen... Read More
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
06/05/2025
Locations: Bloomington Public Schools District 87, Bloomington, Illinois
Conditions: Achievement, Weight Change, Cognition, Fitness, Nutrition Status
Register for Updates
Testing the Effectiveness and Implementation of a Meditation App for Youth in the Legal System
NCT06997120
Recruiting
The goals of this hybrid type 2 randomized controlled trial (RCT) are to evaluate the effectiveness and individual-level implementation of a 1-month app-based meditation program with youth on probation in Cook County, IL. The primary questions it is designed to answer are: 1. Is the meditation app associated with improvements in behavioral health outcomes including cannabis use problems? 2. Do improvements in emotion regulation appear to mediate the effects of the meditation app on these behavi... Read More
Gender:
ALL
Ages:
Between 13 years and 20 years
Trial Updated:
06/05/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Behavioral Health
Register for Updates
A Clinical Study of MK-1084 in Participants With Renal Impairment (MK-1084-010)
NCT06814119
Recruiting
The goal of this study is to learn what happens to MK-1084 levels in a person's body over time. Researchers will measure what happens to MK-1084 levels in the body when it is given to people with moderate or severe renal impairment (RI) (meaning the kidneys do not work properly) as compared to people who are in good health. Researchers also want to learn about the safety of MK-1084 when it is given to people with RI and if people with RI can tolerate it.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/05/2025
Locations: Research by Design ( Site 0001), Chicago, Illinois
Conditions: Healthy, Renal Impairment
Register for Updates
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773
Recruiting
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision. Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Ava... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/05/2025
Locations: Illinois Eye Center, Peoria, Illinois
Conditions: Geographic Atrophy, Macular Degeneration
Register for Updates
JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency
NCT06662188
Recruiting
This is a Phase 1/2, first in human, open-label, dose-escalation study to evaluate the safety, tolerability, and clinical activity of a single dose of JAG201 administered via intracerebroventricular (ICV) injection in pediatric and adult participants with SHANK3 haploinsufficiency resulting from SHANK3 loss of function mutations and chromosomal deletions encompassing the SHANK3 gene. Clinical data will be evaluated for safety, tolerability, and preliminary clinical activity of JAG201 in pediatri... Read More
Gender:
ALL
Ages:
Between 2 years and 9 years
Trial Updated:
06/05/2025
Locations: Rush University, Chicago, Illinois
Conditions: SHANK3 Haploinsufficiency, Phelan-McDermid Syndrome
Register for Updates